And during past decades, the beneficial effect of FGF21 analogs and FGF21-receptor agonists confirmed by preclinical and clinical experiments has indicated that FGF21 is an attractive target for the treatment of metabolic diseases, particularly for obesity, T2DM, and NASH. The gene discussed is FGF21; the disease is obesity disorder.